Want to see FSNUY full AI Analyst Report?
Top Page
Fresenius SE & Co
(OTC:FSNUY)
Select Model
Select Model
Rating:72Outperform
Price Target:
$13.50
▲(0.90% Upside)
Action:Upgraded
Date:08/10/26
FSNUY scores well on improving financial performance (growth, margin recovery, and lower leverage) and a strong, confidence-boosting earnings update with raised EPS guidance. The overall score is held back by stretched technical momentum (RSI/Stoch overbought signals) and uneven cash-flow conversion/volatility despite positive free cash flow.
Positive Factors
Raised earnings outlook
The higher EPS outlook reflects strong first-half execution, including double-digit EBIT and core EPS growth, while management expects continued delivery in the second half. Raised guidance provides evidence of improving earnings power and supports confidence in the operating model over the next several quarters.
Negative Factors
FDA remediation risk
The FDA finding creates a continuing compliance and execution obligation at a U.S. manufacturing site. Management expects no material near-term financial impact, but required remediation could consume resources and remains a structural risk to production reliability, regulatory standing and pharmaceutical execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Raised earnings outlook
The higher EPS outlook reflects strong first-half execution, including double-digit EBIT and core EPS growth, while management expects continued delivery in the second half. Raised guidance provides evidence of improving earnings power and supports confidence in the operating model over the next several quarters.
Read all positive factors
Fresenius SE & Co (FSNUY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$27.10B
Dividend Yield2.58%
Average Volume (3M)8.15K
Price to Earnings (P/E)15.1
Beta (1Y)0.40
Revenue Growth12.91%
EPS Growth44.43%
CountryUS
Employees178,394
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.17
Shares Outstanding2,252,949,200
10 Day Avg. Volume0
30 Day Avg. Volume8,151
Financial Highlights & Ratios
PEG Ratio0.57
Price to Book (P/B)5.76
Price to Sales (P/S)5.00
P/FCF Ratio95.51
Enterprise Value/Market Cap1.41
Enterprise Value/Revenue1.62
Enterprise Value/Gross Profit6.42
Enterprise Value/Ebitda11.16
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.05
Revenue Forecast (FY)$27.40B
Fresenius SE & Co Business Overview & Revenue Model
Company Description
Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresen...
Fresenius SE & Co Earnings Call Summary
Earnings Call Date:Aug 04, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 04, 2026
Earnings Call Sentiment Positive
The call was decisively positive: management reported broad‑based operational momentum across Kabi, biopharma, MedTech and Helios, delivered strong Q2 results (core EPS +14% CER, EBIT +10% CER), expanded margins and ROIC, strengthened cash generation and raised full‑year core EPS guidance to 10%–15%. Noted risks — an OAI at a U.S. manufacturing site, isolated manufacturing adjustments, China VBP headwinds, regional softness in parts of Helios and external input‑cost pressures — are acknowledged and being managed, but they do not materially detract from the upbeat operational and financial story presented.Positive Updates
Raised Full‑Year Core EPS Guidance
Upgraded full‑year core EPS growth guidance to 10%–15% at constant currency (previously 5%–10%), reflecting strong H1 delivery and confidence in second‑half phasing.
Negative Updates
FDA Inspection — OAI at Melrose Park
U.S. FDA inspection resulted in 'Official Action Indicated' (OAI) status at the Melrose Park site (other U.S. sites VAI). Management expects no material impact on production, supply or full‑year financials but remediation is required and remains a risk to monitor.
Read all updates
Q2-2026 Updates
Positive
Negative
Raised Full‑Year Core EPS Guidance
Upgraded full‑year core EPS growth guidance to 10%–15% at constant currency (previously 5%–10%), reflecting strong H1 delivery and confidence in second‑half phasing.
Read all positive updates
Company Guidance
Fresenius raised its full‑year core EPS growth guidance to 10–15% at constant currency (up from 5–10%), driven by strong H1 results (Q2 core EPS +14% CER, EBIT +10% CER, group EBIT margin +60 bps to 12.3%); key planning assumptions include Kabi EBIT margin at the upper end of the 16.5–17% range, interest expense slightly below prior year, CapEx around 5.5% of revenue, and a modest FX sensitivity (spot rates as of 30 June would give <1% upside to reported revenue, EBIT and net income). Management flagged Kabi’s growth vectors (Kabi organic +7% in Q2, biopharma +38%, growth vectors +12%, MedTech +11%) and the full annualisation of China keto/VBP effects from Q3 as important drivers, noted Helios seasonality (Q3) and a tough Q4 compare (surcharge to Oct‑26), reiterated Helios’ structural EBIT margin ambition of 10–12% and expected EBIT growth for 2027, and emphasized balance‑sheet strength (net debt/EBITDA ~2.6x within 2.5–3x target, LTM operating cash flow €2.8bn, LTM free cash flow €1.6bn, LTM cash conversion 1.2, ROIC ~6.9% vs 6–8% ambition).Fresenius SE & Co Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
67
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.53B | 21.97B | 21.83B | 22.30B | 40.84B | 37.52B |
| Gross Profit | 5.94B | 5.47B | 5.38B | 5.06B | 10.72B | 10.31B |
| EBITDA | 3.42B | 3.17B | 3.14B | 2.73B | 3.10B | 6.86B |
| Net Income | 1.53B | 1.21B | 471.00M | -594.00M | 1.37B | 1.82B |
Balance Sheet | ||||||
| Total Assets | 41.83B | 41.38B | 43.55B | 45.28B | 76.42B | 71.96B |
| Cash, Cash Equivalents and Short-Term Investments | 1.28B | 1.58B | 2.05B | 2.56B | 2.35B | 2.75B |
| Total Debt | 11.41B | 11.93B | 13.58B | 15.83B | 27.76B | 27.16B |
| Total Liabilities | 21.44B | 21.62B | 23.26B | 25.63B | 44.20B | 42.67B |
| Stockholders Equity | 19.69B | 19.10B | 19.54B | 19.00B | 20.41B | 19.00B |
Cash Flow | ||||||
| Free Cash Flow | 1.42B | 1.15B | 1.52B | 3.32B | 2.28B | 3.03B |
| Operating Cash Flow | 2.93B | 2.59B | 2.45B | 4.46B | 4.20B | 5.08B |
| Investing Cash Flow | -759.28M | -904.82M | -510.00M | -3.19B | -2.61B | -2.82B |
| Financing Cash Flow | -2.21B | -2.32B | -2.18B | -1.38B | -1.60B | -1.45B |
Fresenius SE & Co Technical Analysis
Negative
13.38
Price Trends
13.10
Negative
12.29
Negative
12.94
Negative
Market Momentum
-0.22
Positive
32.80
Neutral
0.86
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FSNUY, the sentiment is Negative. The current price of 13.38 is above the 20-day moving average (MA) of 12.86, above the 50-day MA of 13.10, and above the 200-day MA of 12.94, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 32.80 is Neutral, neither overbought nor oversold. The STOCH value of 0.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FSNUY.
Fresenius SE & Co Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $27.10B | 15.12 | 7.89% | 2.58% | 12.91% | 44.43% | |
70 Outperform | $20.92B | 9.98 | 50.63% | ― | 5.43% | 65.86% | |
69 Neutral | $4.64B | 23.35 | 15.83% | ― | 5.95% | 5.33% | |
62 Neutral | $95.08B | 14.85 | -112.87% | 0.69% | 7.31% | 25.54% | |
60 Neutral | $11.28B | 15.22 | -123.56% | ― | 6.45% | 16.30% | |
60 Neutral | $11.16B | 11.06 | 7.21% | 4.14% | 6.76% | 57.96% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
FSNUY
Fresenius SE & Co
11.65
-2.29
-16.40%
OPCH
Option Care Health
31.05
4.25
15.86%
DVA
DaVita
177.02
50.64
40.07%
FMS
Fresenius Medical Care
20.88
-5.54
-20.97%
HCA
HCA Healthcare
445.01
28.99
6.97%
THC
Tenet Healthcare
260.57
65.72
33.73%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.